Small Molecule Allosteric Modulation of the Adenosine A Receptor

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Jul 12

PMID 37435481

Authors

Anh T N Nguyen

Quan L Tran

Jo-Anne Baltos

Samantha M McNeill

Diep T N Nguyen

Lauren T May

Affiliations

Soon will be listed here.

Abstract

G protein-coupled receptors (GPCRs) represent the target for approximately a third of FDA-approved small molecule drugs. The adenosine A receptor (AR), one of four adenosine GPCR subtypes, has important (patho)physiological roles in humans. AR has well-established roles in the regulation of the cardiovascular and nervous systems, where it has been identified as a potential therapeutic target for a number of conditions, including cardiac ischemia-reperfusion injury, cognition, epilepsy, and neuropathic pain. AR small molecule drugs, typically orthosteric ligands, have undergone clinical trials. To date, none have progressed into the clinic, predominantly due to dose-limiting unwanted effects. The development of AR allosteric modulators that target a topographically distinct binding site represent a promising approach to overcome current limitations. Pharmacological parameters of allosteric ligands, including affinity, efficacy and cooperativity, can be optimized to regulate AR activity with high subtype, spatial and temporal selectivity. This review aims to offer insights into the AR as a potential therapeutic target and highlight recent advances in the structural understanding of AR allosteric modulation.

Citing Articles

Selective modulation of epileptic tissue by an adenosine A receptor-activating drug.

Ghosh A, Ribeiro-Rodrigues L, Ruffolo G, Alfano V, Domingos C, Rei N Br J Pharmacol. 2024; 181(24):5041-5061.

PMID: 39300608 PMC: 11578780. DOI: 10.1111/bph.17319.

The Bifunctional Dimer Caffeine-Indan Attenuates α-Synuclein Misfolding, Neurodegeneration and Behavioral Deficits after Chronic Stimulation of Adenosine A1 Receptors.

Jakova E, Aigbogun O, Moutaoufik M, Allen K, Munir O, Brown D Int J Mol Sci. 2024; 25(17).

PMID: 39273333 PMC: 11395333. DOI: 10.3390/ijms25179386.

Lipid Trolling to Optimize A Adenosine Receptor-Positive Allosteric Modulators (PAMs).

Pradhan B, Pavan M, Fisher C, Salmaso V, Wan T, Keyes R J Med Chem. 2024; 67(14):12221-12247.

PMID: 38959401 PMC: 11636968. DOI: 10.1021/acs.jmedchem.4c00944.

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives.

Areias F, Correia C, Rocha A, Teixeira S, Castro M, Brea J Molecules. 2024; 29(11).

PMID: 38893418 PMC: 11173536. DOI: 10.3390/molecules29112543.

2-Amino-5-arylethynyl-thiophen-3-yl-(phenyl)methanones as A Adenosine Receptor Positive Allosteric Modulators.

Oliva P, Suresh R, Pasquini S, Salmaso V, Will E, Tosh D ACS Med Chem Lett. 2023; 14(12):1640-1646.

PMID: 38116442 PMC: 10726435. DOI: 10.1021/acsmedchemlett.3c00315.

References

Ross A, Gibbons R, Stone G, Kloner R, Alexander R . A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005; 45(11):1775-80. DOI: 10.1016/j.jacc.2005.02.061. View

Johansson B, Halldner L, Dunwiddie T, Masino S, Poelchen W, Gimenez-Llort L . Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci U S A. 2001; 98(16):9407-12. PMC: 55434. DOI: 10.1073/pnas.161292398. View

Gao Z, Jacobson K . Purinergic Signaling in Mast Cell Degranulation and Asthma. Front Pharmacol. 2018; 8:947. PMC: 5744008. DOI: 10.3389/fphar.2017.00947. View

Yang Z, Cerniway R, Byford A, Berr S, French B, Matherne G . Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol. 2002; 282(3):H949-55. DOI: 10.1152/ajpheart.00741.2001. View

Johansson S, Salehi A, Sandstrom M, Westerblad H, Lundquist I, Carlsson P . A1 receptor deficiency causes increased insulin and glucagon secretion in mice. Biochem Pharmacol. 2007; 74(11):1628-35. DOI: 10.1016/j.bcp.2007.08.006. View

Latini S, Pedata F . Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem. 2001; 79(3):463-84. DOI: 10.1046/j.1471-4159.2001.00607.x. View

Romagnoli R, Baraldi P, IJzerman A, Massink A, Cruz-Lopez O, Lopez-Cara L . Synthesis and biological evaluation of novel allosteric enhancers of the A1 adenosine receptor based on 2-amino-3-(4'-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene. J Med Chem. 2014; 57(18):7673-86. DOI: 10.1021/jm5008853. View

Hausenloy D, Yellon D . Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007; 12(3-4):217-34. DOI: 10.1007/s10741-007-9026-1. View

Baraldi P, Pavani M, Shryock J, Moorman A, Iannotta V, Borea P . Synthesis of 2-amino-3-heteroaroylthiophenes and evaluation of their activity as potential allosteric enhancers at the human A1 receptor. Eur J Med Chem. 2004; 39(10):855-65. DOI: 10.1016/j.ejmech.2004.06.009. View

10.

Romagnoli R, Baraldi P, Carrion M, Cara C, Cruz-Lopez O, Iaconinoto M . Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor. J Med Chem. 2008; 51(18):5875-9. DOI: 10.1021/jm800586p. View

11.

Resta R, Yamashita Y, Thompson L . Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998; 161:95-109. DOI: 10.1111/j.1600-065x.1998.tb01574.x. View

12.

Baraldi P, Zaid A, Lampronti I, Fruttarolo F, Pavani M, Tabrizi M . Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg Med Chem Lett. 2000; 10(17):1953-7. DOI: 10.1016/s0960-894x(00)00379-6. View

13.

Dennis D, Raatikainen M, Martens J, Belardinelli L . Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Circulation. 1996; 94(10):2551-9. DOI: 10.1161/01.cir.94.10.2551. View

14.

Do H, Wang J, Bhattarai A, Miao Y . GLOW: A Workflow Integrating Gaussian-Accelerated Molecular Dynamics and Deep Learning for Free Energy Profiling. J Chem Theory Comput. 2022; 18(3):1423-1436. PMC: 9773012. DOI: 10.1021/acs.jctc.1c01055. View

15.

Zimmermann H, Braun N, Kegel B, Heine P . New insights into molecular structure and function of ectonucleotidases in the nervous system. Neurochem Int. 1998; 32(5-6):421-5. DOI: 10.1016/s0197-0186(97)00126-5. View

16.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

17.

Draper-Joyce C, Bhola R, Wang J, Bhattarai A, Nguyen A, Cowie-Kent I . Positive allosteric mechanisms of adenosine A receptor-mediated analgesia. Nature. 2021; 597(7877):571-576. PMC: 8711093. DOI: 10.1038/s41586-021-03897-2. View

18.

Matherne G, Linden J, Byford A, Gauthier N, Headrick J . Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci U S A. 1997; 94(12):6541-6. PMC: 21086. DOI: 10.1073/pnas.94.12.6541. View

19.

Bright R, Mochly-Rosen D . The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke. 2005; 36(12):2781-90. DOI: 10.1161/01.STR.0000189996.71237.f7. View

20.

Peleli M, Fredholm B, Sobrevia L, Carlstrom M . Pharmacological targeting of adenosine receptor signaling. Mol Aspects Med. 2017; 55:4-8. DOI: 10.1016/j.mam.2016.12.002. View